Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Instagram Outage Disrupts Thousands of U.S. Users 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
